OR WAIT null SECS
March 17, 2021
The Federal Trade Commission is launching a broad review of drug-company mergers, with an eye to examining how such actions can harm competition in the biopharmaceutical industry.
The transaction is set to close during the first half of 2021 and is expected to enhance drug substance and drug product capabilities for WuXi.
March 15, 2021
The acquisition will expand the antimicrobial and antiviral testing capabilities of Sotera’s Nelson Labs business in the US.
March 11, 2021
Through the acquisition, Takeda will have access to Maverick’s T-cell engager COBRA platform, along with its development portfolio.
March 10, 2021
Through the acquisition, Amgen will have access to Five Prime’s oncology portfolio, which includes bemarituzumab, Five Prime’s Phase-III ready anti-FGFR2b antibody.
March 03, 2021
Arcline Investment Management has acquired ChargePoint Technology, strengthening its global presence.
March 02, 2021
Under the terms of the acquisition, OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies, WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit.
March 01, 2021
The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.
Through the acquisition, Merck will have access to Pandion’s pipeline of precision immune modulators targeting critical immune control nodes, including its lead candidate, PT101.
February 24, 2021
Through the acquisition, PharmaLex will expand its capabilities in the biopharma sector while enhancing its global market reach with a new location in Australia.
